In the assessment of 12-month price targets, analysts unveil insights for Gilead Sciences, presenting an average target of ...

HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 ...

Tyler Van Buren, an analyst from TD Cowen, maintained the Buy rating on Gilead Sciences (GILD – Research Report). The associated price target ...

Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company renowned for its antiviral drugs used for the treatment of HIV, hepatitis, and other critical diseases. Gilead Sciences ...

Biotech giant Gilead Sciences, Inc. GILD has put up a strong ... Gilead has a market-leading portfolio of HIV treatments. The company’s consistent efforts to develop additional innovative ...

Cognizant and Gilead expand partnership to drive greater value through advanced technology applications: Teaneck, New Jersey Friday, January 31, 2025, 14:00 Hrs [IST] Cognizant ha ...

The the stock of HIV and hepatitis C drugmaker has fallen ... alike will be keeping a close eye on the performance of Gilead Sciences in its upcoming earnings disclosure. The company's earnings ...

Gilead Sciences, Inc. (NASDAQ:GILD), a leading biopharmaceutical company with a market capitalization of $119.32 billion, has been making significant strides in its core HIV franchise while expanding ...